Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
25.2M
-
Number of holders
-
42
-
Total 13F shares, excl. options
-
4.36M
-
Shares change
-
-78.4K
-
Total reported value, excl. options
-
$5.23M
-
Value change
-
-$105K
-
Put/Call ratio
-
0
-
Number of buys
-
13
-
Number of sells
-
-14
-
Price
-
$1.20
Significant Holders of Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share (AXDX) as of Q4 2024
48 filings reported holding AXDX - Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share as of Q4 2024.
Accelerate Diagnostics, Inc - Common Stock, $0.001 par value per share (AXDX) has 42 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.36M shares
of 25.2M outstanding shares and own 17.27% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (2.08M shares), GRIFFIN ASSET MANAGEMENT, INC. (1M shares), VANGUARD GROUP INC (478K shares), GEODE CAPITAL MANAGEMENT, LLC (136K shares), Cannell & Spears LLC (115K shares), RENAISSANCE TECHNOLOGIES LLC (107K shares), TCI Wealth Advisors, Inc. (55.6K shares), BlackRock, Inc. (50.8K shares), Cladis Investment Advisory, LLC (42.7K shares), and CITADEL ADVISORS LLC (35.4K shares).
This table shows the top 42 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.